Loading...
Loading...
Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings, Inc.. Spoken Alpha tracks COAG's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks COAG's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 4/10 quarters with 70% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Missed in 3 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for COAG.
curl https://api.spokenalpha.com/v1/companies/COAG| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.03 | $2.95 | +2.8% | +3.3% | +0.5% |
| Q4 FY2026 | $2.95 | $3.12 | -5.6% | +2.6% | +4.3% |
| Q3 FY2026 | $2.99 | $3.08 | -2.9% | +6.0% | +8.9% |
| Q2 FY2026 | $2.75 | $2.90 | -5.1% | -3.3% | -2.7% |
| Q1 FY2025 | $3.02 | $3.06 | -1.3% | +1.3% | -0.3% |
| Q4 FY2025 | $3.15 | $3.04 | +3.5% | +3.6% | +6.5% |
| Q3 FY2025 | $3.22 | $3.14 | +2.7% | +1.1% | +0.9% |
| Q2 FY2025 | $3.31 | $3.21 | +3.0% | -0.4% | +1.1% |
| Q1 FY2024 | $3.13 | $3.15 | -0.6% | -1.3% | +0.8% |
| Q4 FY2024 | $2.93 | $3.29 | -10.8% | +3.6% | +3.7% |